4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.60
-0.09 (-1.04%)
At close: May 22, 2026, 4:00 PM EDT
8.57
-0.03 (-0.35%)
After-hours: May 22, 2026, 6:14 PM EDT
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 196 employees as of December 31, 2025. The number of employees decreased by 31 or -13.66% compared to the previous year.
Employees
196
Change (1Y)
-31
Growth (1Y)
-13.66%
Revenue / Employee
$450,214
Profits / Employee
-$820,903
Market Cap
449.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 196 | -31 | -13.66% |
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Jun 30, 2024 | 201 | 64 | 46.72% |
| Mar 31, 2024 | 171 | 34 | 24.82% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Sep 30, 2023 | 144 | 4 | 2.86% |
| Jun 30, 2023 | 137 | -1 | -0.72% |
| Mar 31, 2023 | 137 | 0 | - |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Sep 30, 2022 | 140 | 19 | 15.70% |
| Jun 30, 2022 | 138 | 34 | 32.69% |
| Mar 31, 2022 | 137 | 49 | 55.68% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Sep 30, 2021 | 121 | 43 | 55.13% |
| Jun 30, 2021 | 104 | 26 | 33.33% |
| Mar 31, 2021 | 88 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| ADC Therapeutics | 193 |
| Neurogene | 131 |
| Ocugen | 116 |
| Prelude Therapeutics | 79 |
| Upstream Bio | 75 |
| Assembly Biosciences | 73 |
| Fulcrum Therapeutics | 55 |
FDMT News
- 6 days ago - 4D Molecular Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 9 days ago - 4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy - MarketBeat
- 10 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 12 days ago - 4D Molecular Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 17 days ago - 4D Molecular price target lowered to $33 from $38 at Goldman Sachs - TheFly
- 18 days ago - 4D Molecular files $400M mixed securities shelf - TheFly
- 18 days ago - 4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 18 days ago - 4D Molecular Therapeutics Registration statement: Registration filing - Filings